BeOne Medicines Ltd. American Depositary Shares — gráfico, cotizaciones y noticias (NASDAQ:ONC)

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Trimestre Año

Market Capitalization 34.6991 B
Employee 12 K
Founded 2010
CEO John Vincent OylerJohn Vincent Oyler
Website www.beonemedicines.com
Headquarter N/A
FIGI BBG00B6WF7T5
Industry Technology

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

34.7 B Capitalización de mercado

Ratio precio/beneficio

1 599

Relación precio/flujo de caja

83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.